Roles of serum irisin and soluble Corin in prognosis assessment of elderly patients with chronic heart failure

doi:10.3969/j.issn.1673-8640.2024.09.003

Abstract

Abstract:

Objective To investigate the roles of serum irisin and soluble Corin in prognosis assessment of elderly patients with chronic heart failure （CHF）. Methods A total of 129 elderly patients with CHF were enrolled from the General Hospital of Chinese People's Liberation Army Northern Theater Command from March 2016 to February 2019. The clinical data of all the patients were collected，and blood routine test，routine biochemical parameters，serum irisin，soluble Corin levels and left ventricular ejection fraction （LVEF） were determined. All the patients were followed up，and the end point of follow-up was all-cause death or major adverse cardiovascular events. The patients with end point events were included in poor prognosis group，and those without end point events were included in good prognosis group. Pearson correlation was used to assess the correlation between indexes. Receiver operating characteristic（ROC）curve was used to determine the optimal cut-off value of serum irisin and soluble Corin to determine the end point events in elderly CHF patients. Kaplan-Meier survival curve was used to analyze the survival of elderly patients with CHF. Cox regression analysis was used to evaluate the risk factors of poor prognosis in elderly patients with CHF. Results There was no statistical significance in clinical data among elderly CHF patients with different New York Heart Association （NYHA）grades（P>0.05）. There was no statistical significance in irisin and soluble Corin levels among elderly CHF patients of different genders （P>0.05）. Serum irisin and soluble Corin had no correlation with N-terminal pro-B-type natriuretic peptide（NT-proBNP） and LVEF （P>0.05）. The levels of serum irisin and soluble Corin in poor prognosis group were lower than those in good prognosis group （P<0.05）. The free end point event survival times of irisin >5.7 ng·mL-1 group and soluble Corin>487 pg·mL-1 group were longer than those of irisin ≤5.7 ng·mL-1 group and soluble Corin≤487 pg·mL-1 group，respectively （P<0.01）. Age >70 years old，combined with atrial fibrillation，NYHAⅡ-Ⅲ，combined with anemia，elevated serum creatinine（SCr），NT-proBNP>1 000 pg·mL-1，LVEF<50%，serum irisin≤ 5.7 ng·mL-1，soluble Corin≤487 pg·mL-1 were independent risk factors for poor prognosis （major adverse cardiovascular events and all-cause death） in elderly patients with CHF. Conclusions Serum irisin and soluble Corin have good predictive value for major adverse cardiovascular events and all-cause death in elderly patients with CHF，and may be used as prognostic indexes for elderly patients with CHF.

Key words: Irisin, Soluble Corin, Chronic heart failure, Elderly patient, Prognosis assessment

CLC Number:

R446.1

LI Kun, HU Bingtao, WAN Nan. Roles of serum irisin and soluble Corin in prognosis assessment of elderly patients with chronic heart failure[J]. Laboratory Medicine, 2024, 39(9): 834-840.

Figures/Tables 6

References 18

[1]	SKRZYPEK A, MOSTOWIK M, SZELIGA M, et al. Chronic heart failure in the elderly:still a current medical problem[J]. Folia Med Cracov, 2018, 58(4):47-56.
[2]	KITAHARA T, SHISHIDO T, SUZUKI S, et al. Serum midkine as a predictor of cardiac events in patients with chronic heart failure[J]. J Card Fail, 2010, 16(4):308-313. DOI PMID
[3]	HO M Y, WANG C Y. Role of irisin in myocardial infarction,heart failure,and cardiac hypertrophy[J]. Cells, 2021, 10(8):2103.
[4]	BEREZIN A A, OBRADOVIC A B, FUSHTEY I M,et al. Low plasma levels of irisin predict acutely decompensated heart failure in type 2 diabetes mellitus patients with chronic heart failure[J]. J Cardiovasc Dev Dis, 2023, 10(4):136.
[5]	PELEG A, GHANIM D, VERED S, et al. Serum corin is reduced and predicts adverse outcome in non-ST-elevation acute coronary syndrome[J]. Eur Heart J Acute Cardiovasc Care, 2013, 2(2):159-165. DOI PMID
[6]	YU Z, LU X, XU W, et al. Serum corin is associated with the risk of chronic heart failure[J]. Oncotarget, 2017, 8(59):100353-100357.
[7]	MANT J, AL-MOHAMMAD A, SWAIN S, et al. Management of chronic heart failure in adults:synopsis of the National Institute for Health and clinical excellence guideline[J]. Ann Intern Med, 2011, 155(4):252-259.
[8]	TROMP J, SHEN L, JHUND P S, et al. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction[J]. J Am Coll Cardiol, 2019, 74(5):601-612.
[9]	LAGZDINA R, RUMAKA M, GERSONE G, et al. Circulating irisin in healthy adults:changes after acute exercise,correlation with body composition,and energy expenditure parameters in cross-sectional study[J]. Medicina(Kaunas), 2020, 56(6):274.
[10]	LI J, XIE S, GUO L, et al. Irisin:linking metabolism with heart failure[J]. Am J Transl Res, 2020, 12(10):6003-6014.
[11]	BEREZIN A A, FUSHTEY I M, PAVLOV S V, et al. Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus[J]. Mol Biomed, 2022, 3(1):34. DOI PMID
[12]	SILVESTRINI A, BRUNO C, VERGANI E, et al. Circulating irisin levels in heart failure with preserved or reduced ejection fraction:a pilot study[J]. PLoS One, 2019, 14(1):e0210320.
[13]	FU J, LI F, TANG Y, et al. The emerging role of irisin in cardiovascular diseases[J]. J Am Heart Assoc, 2021, 10(20):e022453.
[14]	NIU Y, ZHANG S, GU X, et al. Recombinant soluble corin improves cardiac function in mouse models of heart failure[J]. J Am Heart Assoc, 2021, 10(7):e019961.
[15]	NIU Y, ZHOU T, ZHANG S, et al. Corin deficiency impairs cardiac function in mouse models of heart failure[J]. Front Cardiovasc Med, 2023,10:1164524.
[16]	牛亚燕, 张胜南, 周田甜. 可溶性corin在心力衰竭中的研究进展[J]. 中国血液流变学杂志, 2019, 29(1):120-123.
[17]	ZHOU X, CHEN J C, LIU Y, et al. Plasma corin as a predictor of cardiovascular events in patients with chronic heart failure[J]. JACC Heart Fail, 2016, 4(8):664-669.
[18]	CHEN L, ZHANG Q, ZHANG M, et al. Soluble corin predicts the risk of cardiovascular disease:a 10-year follow-up study[J]. JACC Asia, 2022, 2(4):490-501.

NYHA分级	例数		年龄/岁	性别			CHF病因
NYHA分级	例数		年龄/岁	男/ [例（%）]		女/ [例（%）]	CAD/ [例（%）]	瓣膜性心脏病/ [例（%）]	高血压心脏病/[例（%）]	原发性心肌病/[例（%）]
Ⅰ级	15		71.96±4.52	9（60.00）		6（40.00）	9（60.00）	4（26.67）	1（6.67）	1（6.67）
Ⅱ级	68		72.95±5.05	47（69.12）		21（30.88）	32（47.06）	23（33.82）	10（14.71）	3（4.41）
Ⅲ级	46		72.49±4.95	30（65.22）		16（34.78）	26（56.52）	12（26.09）	7（15.22）	1（2.17）
统计值			0.290	0.530			2.650
P值			0.750	0.770			0.850
NYHA分级		既往史						伴发疾病
NYHA分级		脑梗死/[例（%）]			AMI/[例（%）]			高血压/[例（%）]	糖尿病/[例（%）]	心房颤动/[例（%）]
Ⅰ级		3（20.00）			7（46.67）			12（80.00）	5（33.33）	4（26.67）
Ⅱ级		13（19.12）			28（41.18）			55（80.88）	22（32.35）	15（22.06）
Ⅲ级		9（19.57）			21（45.65）			41（89.13）	17（36.96）	11（23.91）
统计值		0.008			0.300			1.540	0.260	0.160
P值		0.990			0.860			0.460	0.880	0.920

NYHA分级	例数		年龄/岁	性别			CHF病因
NYHA分级	例数		年龄/岁	男/ [例（%）]		女/ [例（%）]	CAD/ [例（%）]	瓣膜性心脏病/ [例（%）]	高血压心脏病/[例（%）]	原发性心肌病/[例（%）]
Ⅰ级	15		71.96±4.52	9（60.00）		6（40.00）	9（60.00）	4（26.67）	1（6.67）	1（6.67）
Ⅱ级	68		72.95±5.05	47（69.12）		21（30.88）	32（47.06）	23（33.82）	10（14.71）	3（4.41）
Ⅲ级	46		72.49±4.95	30（65.22）		16（34.78）	26（56.52）	12（26.09）	7（15.22）	1（2.17）
统计值			0.290	0.530			2.650
P值			0.750	0.770			0.850
NYHA分级		既往史						伴发疾病
NYHA分级		脑梗死/[例（%）]			AMI/[例（%）]			高血压/[例（%）]	糖尿病/[例（%）]	心房颤动/[例（%）]
Ⅰ级		3（20.00）			7（46.67）			12（80.00）	5（33.33）	4（26.67）
Ⅱ级		13（19.12）			28（41.18）			55（80.88）	22（32.35）	15（22.06）
Ⅲ级		9（19.57）			21（45.65）			41（89.13）	17（36.96）	11（23.91）
统计值		0.008			0.300			1.540	0.260	0.160
P值		0.990			0.860			0.460	0.880	0.920

性别	例数	鸢尾素/ （ng·mL^-1）	可溶性Corin/（pg·mL^-1）
男性	86	5.03±1.81	531.83±184.24
女性	43	5.51±2.21	538.02±155.11
t值		1.320	0.190
P值		0.190	0.850

性别	例数	鸢尾素/ （ng·mL^-1）	可溶性Corin/（pg·mL^-1）
男性	86	5.03±1.81	531.83±184.24
女性	43	5.51±2.21	538.02±155.11
t值		1.320	0.190
P值		0.190	0.850

性别	例数	鸢尾素/ （ng·mL^-1）	可溶性Corin/（pg·mL^-1）
预后良好组	45	5.76±2.03	599.42±156.63
预后不良组	84	4.88±1.86	498.79±174.26
t值		2.480	3.240
P值		0.020	0.002